Skip to main content
TipRanks
Go Ultimate75% OFF

Perrigo Company (PRGO) AI Stock Analysis

724 Followers
PRGO

Perrigo Company

(NYSE:PRGO)

Select Model
Rating:56Neutral
Price Target:$16.00â–²(1.52% Upside)
Action:reiterated
Date:11/04/26

The score is held back primarily by weak financial performance (deep losses, very negative margins/ROE, and balance-sheet uncertainty), partially offset by positive free cash flow. The earnings call adds a mixed-but-improving view (cost savings and portfolio simplification, but lowered 2026 outlook and high leverage). Technicals are moderately supportive with price above key longer-term averages and a positive MACD, while valuation benefits from a high dividend yield but is constrained by loss-driven negative P/E.

Positive Factors
Positive Cash GenerationPerrigo continues to generate positive operating and free cash flow despite reported net losses, providing liquidity to support operations and investment. Although cash generation has weakened, this recurring cash base can help fund the core business and reduce financial strain while profitability is repaired.
Negative Factors
Deep Profitability WeaknessPerrigo's severe net losses and deeply negative margin indicate that current earnings power is not supporting the business adequately. The deterioration is more serious than modest revenue softness, and continued losses could restrict reinvestment, weaken shareholder returns, and prolong the recovery in profitability.

Perrigo Company (PRGO) vs. SPDR S&P 500 ETF (SPY)

-40%-20%0%20%40%60%PRGO+40.68%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$2.19B
Dividend Yield
7.36%
Average Volume (3M)
2.56M
Price to Earnings (P/E)
-1.2
Beta (1Y)
0.96
Revenue Growth
-4.45%
EPS Growth
-3289.03%
Country
US
Employees
8,100
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Perrigo Company Business Overview & Revenue Model

Company Description

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper res...

How the Company Makes Money

Perrigo primarily makes money by selling consumer self-care products through two main routes: (1) private-label/store-brand manufacturing and supply, and (2) branded OTC/self-care products sold under Perrigo-owned brands. For private-label, Perrigo e...

Perrigo Company Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:0.38%|Next Earnings Date:Mar 01, 2027
Earnings Call SentimentNeutral

The call presented a mixed but improving picture. Perrigo reported sequential improvement in core sales trends and operating margins, meaningful share gains in U.S. store brand OTC and European brands, progress on its Three-S plan, cost savings and a strategically important infant formula divestiture. However, Q3 sales, margins and EPS declined, the company lowered its outlook because of cautious retailer inventory positioning and continued European softness, and leverage remains elevated. The positive strategic and operational developments were offset by significant current-period financial pressures.

Positive Updates

Sequential Improvement in Core Performance
Core net sales year-over-year decline moderated from 8.3% in Q1 to 3.1% in Q2 and 1.7% in Q3. Core adjusted operating margin improved sequentially from 12.8% to 13.4% to 14.3%.

Negative Updates

Core and Organic Sales Decline
Core net sales declined 1.7% year-over-year in Q3, while core organic net sales declined 1.1%.

Company Guidance

For 2026, core reported net sales are expected to decline 2.5%-3.6%, organic net sales to decline 2.7%-3.8%, adjusted gross margin to be 37.5%-38.5%, adjusted operating margin to be 14%-15%, and adjusted diluted earnings per share to be $2.15-$2.35; all-in, which now excludes infant formula but includes other divestitures, reported net sales are expected to decline 4.6%-5.7%, adjusted gross margin to be 37.8%-38.8%, adjusted operating margin to be 14.3%-15.3%, and adjusted diluted earnings per share expected to be between $2.25 and $2.45. For both core and all-in, net interest expense is assumed to be approximately $162 million, adjusted effective tax rate approximately 14%, and approximately 140 million diluted shares outstanding, with year-end net leverage of approximately four times adjusted EBITDA and all-in cash from operating activities as a percentage of adjusted net income expected to be in the low to mid-60% range; the Operational Enhancement Program remains on track to deliver approximately $60 million-$80 million in 2026.

Perrigo Company Financial Statement Overview

Summary

Cash flow is a stabilizer (TTM operating cash flow $241M; free cash flow $168M), but profitability is the major weakness: revenue is down slightly (TTM -1.32%) and net margin is deeply negative (-41.9%) with a widening net loss versus 2025. The balance sheet adds uncertainty due to inconsistent debt presentation across periods and very negative ROE (TTM -56.0%), keeping the overall financial profile below average despite positive FCF.

Income Statement

18Very Negative

Balance Sheet

45Neutral

Cash Flow

62Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue4.09B4.25B4.37B4.66B4.45B4.14B
Gross Profit1.32B1.49B1.54B1.68B1.46B1.42B
EBITDA-1.11B-797.90M433.00M525.00M355.50M695.90M
Net Income-1.77B-1.43B-171.80M-12.70M-140.60M-68.90M
Balance Sheet
Total Assets7.48B8.54B9.65B10.81B11.02B10.43B
Cash, Cash Equivalents and Short-Term Investments436.60M531.60M558.80M751.30M600.70M1.86B
Total Debt3.45B3.97B3.62B4.07B4.32B3.69B
Total Liabilities5.04B5.60B5.33B6.04B6.18B5.27B
Stockholders Equity2.44B2.94B4.32B4.77B4.84B5.15B
Cash Flow
Free Cash Flow223.90M145.10M244.60M303.80M210.90M4.20M
Operating Cash Flow296.30M238.50M362.90M405.50M307.30M156.30M
Investing Cash Flow285.10M-75.40M78.80M-77.50M-1.96B1.28B
Financing Cash Flow-572.00M-220.50M-611.00M-187.20M421.60M-178.70M

Perrigo Company Technical Analysis

Technical Analysis SentimentNeutral
Last Price15.76

Price Trends

50DMA15.22Positive
100DMA13.53Positive
200DMA12.23Positive

Market Momentum

MACD0.25Positive
RSI48.78Neutral
STOCH47.85Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRGO, the sentiment is Neutral. The current price of 15.76 is below the 20-day moving average (MA) of 16.06, above the 50-day MA of 15.22, and above the 200-day MA of 12.23, indicating a neutral trend. The MACD of 0.25 indicates Positive momentum. The RSI at 48.78 is Neutral, neither overbought nor oversold. The STOCH value of 47.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PRGO.

Perrigo Company Risk Analysis

Perrigo Company disclosed 2 risk factors in its most recent earnings report. Perrigo Company reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Perrigo Company Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PRGO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
VTRSVTRS67Neutral$23.44B-38.69-4.24%2.35%4.80%82.97%
RDYRDY66Neutral$12.37B41.317.37%0.76%-10.52%-55.45%
TEVATEVA65Neutral$49.04B100.359.18%―2.99%-28.63%
HLNHLN62Neutral$39.63B18.879.89%1.37%4.99%12.37%
AMRXAMRX58Neutral$7.36B48.70131.71%―8.88%2272.07%
PRGOPRGO56Neutral$2.19B-1.25-68.13%7.36%-4.45%-3289.03%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%PRGORDYVTRSTEVAAMRXHLNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PRGO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PRGOPerrigo Company15.764.0434.53%
RDYDr. Reddy's Laboratories Ltd14.790.825.85%
VTRSViatris, Inc.20.4510.35102.46%
TEVATeva Pharmaceutical Industries Limited42.6216.6263.92%
AMRXAmneal Pharma21.129.6083.33%
HLNHaleon PLC Sponsored ADR9.05-0.28-3.01%

Perrigo Company Corporate Events

Business Operations and StrategyM&A Transactions

Perrigo to Divest Infant Formula Business, Refocus Strategy

Neutral
Oct 29, 2026

On October 29, 2026, Perrigo announced that it had entered into a definitive agreement to sell its Infant Formula business, signaling a strategic move to reshape its portfolio and sharpen focus on core consumer self-care operations. The divestiture i...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026